Commercial Regeneron Q1 2026 net income falls 10% to $727m Pharmaceutical Business ReviewOn a non-GAAP basis, net income rose 12% to $1.04bn from $928m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaceutical Business Review On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ray Therapeutics receives EMA PRIME status for gene therapyNext: Norgine gets first EU approval for WHIM syndrome therapy Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
